ReviewMediators of inflammation2017
Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.
Review in Mediators of inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- A Systematic Review on Effect of Bifidobacterium Isolated from Skin Microbiota on GLP-1 Production to Alleviate Human Ailments.Probiotics and antimicrobial proteins · 2026Pooled it
- Inflammatory bowel disease in patients with Hirschsprung's disease: a systematic review and meta-analysis.Pediatric surgery international · 2018Pooled it
- Exploring the novel ameliorative effect of date palm pollen extract in inflammatory bowel disease.Inflammopharmacology · 2026Article
- N-Acetylcysteine, Tiron, and Their Combination: In Vitro Antioxidant and Anti-Inflammatory Activities and Their Protective Effect in a Rat Model of Acetic Acid-Induced Ulcerative Colitis.International journal of molecular sciences · 2026Article
- Timing-dependent protective and therapeutic effects of ethyl pyruvate in trinitrobenzene sulfonic acid-induced experimental colitis.Experimental physiology · 2026Article
- Lapatinib mitigates acetic acid-induced ulcerative colitis and hepatic damage in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Functional Integration of Crosstalk Between Probiotic Lactic Acid Bacteria and Intestinal Immunity Signaling.Probiotics and antimicrobial proteins · 2026Review
- Pimenta racemosa extract ameliorates chemically induced ulcerative colitis in rats by suppressing inflammation and oxidative stress.Inflammopharmacology · 2026Article
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Geniposide Alleviates Inflammatory Bowel Disease by Regulating Intestinal Flora and Arginine Metabolism and Inhibiting the NF-κB Pathway Through Targeting Anxa5.Mediators of inflammation · 2026Article
- Unraveling the Converging Roles of ASC-Dependent Inflammasomes, Interleukin-1 Superfamily Members, Serum Amyloid A, and Non-Sterile Inflammation in Disease Pathology and Fibrosis in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- Chloride channels and mast cell function: pioneering new frontiers in IBD therapy.Molecular and cellular biochemistry · 2025Review
- Food allergens in immune systems.Food science and biotechnology · 2025Review
- Serum Maresin-1 and Resolvin-D1 Levels as Non-Invasive Biomarkers for Monitoring Disease Activity in Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2025Article
- Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy.International journal of molecular sciences · 2025Review
- Assessment of the Utility of Selected Inflammatory Markers in Correlation with Magnetic Resonance Enterography (MRE) Findings in the Diagnosis of Crohn's Disease.Biomolecules · 2025Article
- The impact of maternal systemic diseases on the occurrence of cleft lip and palate in newborns: a narrative review.Frontiers in public health · 2025Review
- Isoorientin Modulates Gut Microbes and Their Metabolites to Alleviate Caco-2 Cell Monolayer Inflammation by Reducing Intestinal Permeability via P-Gp/eCBs.Journal of inflammation research · 2025Article
- IL-36/IL-36R signaling promotes CD4Frontiers in immunology · 2025Article
- Research advances in nanomaterials with aromatic functional groups for the treatment of inflammatory bowel disease.Frontiers in bioengineering and biotechnology · 2025Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines play an important role in the immunopathogenesis of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, where they drive and regulate multiple aspects of intestinal inflammation. The imbalance between proinflammatory and anti-inflammatory cytokines that occurs in IBD results in disease progression and tissue damage and limits the resolution of inflammation. Targeting cytokines have been novel strategies in the treatment of IBD. Recent studies show the beneficial effects of anticytokine treatments to IBD patients, and multiple novel cytokines are found to be involved in the pathogenesis of IBD. In this review, we will discuss the recent advances of novel biologics in clinics and clinical trials, and novel proinflammatory and anti-inflammatory cytokines found in IBD with focusing on IL-12 family and IL-1 family members as well as their relevance to the potential therapy of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.